Mesoblast is a biopharmaceutical company based in Melbourne that develops off-the-shelf cellular medicines derived from mesenchymal precursor cells. Its product candidates are designed to treat inflammatory and immune-mediated conditions, including graft versus host disease following bone marrow transplantation, chronic heart failure and chronic low back pain. The company works with hospital specialists and clinical researchers to test these cell-based therapies in patients with serious or life-threatening illnesses.
The shares are listed on the Australian Securities Exchange in Australia under the code MSB, and the price on this page is in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Fair price profile
Ranks #715 of 1815 on the Australian Securities Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Australia yet.
TrendFair
51/100
Mixed trend against its averages.
See the numbers →
Above 200-day average-20.2%
From 52-week high-42.3%
MomentumWeak
35/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-24.4%
6-month return-18.8%
12-month, skipping last month-27.5%
Stability (higher is calmer)Fair
68/100
Typical risk for this exchange.
See the numbers →
Volatility, 1 year (lower is calmer)55.6%
Worst drawdown, 1 year (smaller is calmer)-42.3%
LiquidityStrong
89/100
Trades actively.
See the numbers →
Avg daily value traded6.13M AUD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Australia when fundamentals data for this market is added. All Australia stocks.
52-wk range 1.735 – 3.310Daily closes, split-adjusted
Signals
50-day average2.192
200-day average2.218
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.108
Technical summary
Daily
Strongly bearish
3 bullish · 1 neutral · 12 bearish
Weekly
Strongly bearish
1 bullish · 1 neutral · 10 bearish
Monthly
Bearish
2 bullish · 1 neutral · 5 bearish
Moving averages (daily)
SMA 10
1.97
Bearish
EMA 10
1.96
Bearish
SMA 20
2.04
Bearish
EMA 20
2.02
Bearish
SMA 50
2.19
Bearish
EMA 50
2.11
Bearish
SMA 100
2.16
Bearish
EMA 100
2.16
Bearish
SMA 200
2.22
Bearish
EMA 200
2.20
Bearish
Oscillators (daily)
RSI (14)
31.17
Neutral
MACD (12, 26)
-0.07
Bearish
Momentum (12)
-14.49
Bearish
Stochastic %K (14)
8.24
Bullish
Williams %R (14)
-91.76
Bullish
CCI (20)
-197.5
Bullish
Pivot points (classic, last session)
S3
1.53
S2
1.64
S1
1.71
Pivot
1.82
R1
1.89
R2
2.00
R3
2.07
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in AUD. Educational only, not financial advice.
